Clinical pathway for diagnosis and treatment of multiple myeloma in Henan (2024 version)

VernacularTitle:河南省多发性骨髓瘤临床诊疗路径（2024年版）
Keywords: Multiple myeloma; Clinical pathway; Diagnosis; Treatment
From: Journal of Leukemia & Lymphoma 2024;33(11):649-656
CountryChina
Language:Chinese
Abstract: The multiple myeloma (MM) accounts for about 10% of hematologic malignancies, making it the second most common hematologic malignancy, primarily affecting middle-aged and elderly individuals. With continuous advancements in understanding the etiology and pathogenesis of MM, the advent of new drugs and improvements in detection methods, MM has evolved from a tumor with a low treatment response rate to a disease capable of achieving deep remission. However, it remains incurable. Standardized diagnosis and treatment are crucial for prolonging survival and improving the quality of life for MM patients. To enhance the standardized diagnosis and treatment of MM in Henan, and by referring to both domestic and international MM diagnosis and treatment guidelines while considering the specific circumstances of Henan, the expert group members discussed and formulated a clinical pathway for MM diagnosis and treatment. This pathway aims to further improve the level of MM diagnosis and treatment in Henan.